Cytokinetics CYTK Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's financing cash flow?
- Cytokinetics (CYTK) reported financing cash flow of $7.77M in Q1 2026.
- How has Cytokinetics's financing cash flow changed year-over-year?
- Cytokinetics's financing cash flow increased by 63.4% year-over-year, from $4.75M to $7.77M.
- What is the long-term trend for Cytokinetics's financing cash flow?
- Over 4 years (2021 to 2025), Cytokinetics's financing cash flow has grown at a 13.1% compound annual growth rate (CAGR), from $319.98M to $524.46M.
- What does financing cash flow mean?
- The net amount of cash raised from or paid to investors and lenders.
- How do you interpret financing cash flow?
- Positive values indicate net cash inflows from debt or equity, while negative values indicate debt repayment or share buybacks.
- How does financing cash flow compare across companies?
- Highly variable depending on the company's growth stage and capital structure strategy.